Publication: The State of Melanoma: Emergent Challenges and Opportunities.
| dc.contributor.author | Atkins, Michael B | |
| dc.contributor.author | Curiel-Lewandrowski, Clara | |
| dc.contributor.author | Fisher, David E | |
| dc.contributor.author | Swetter, Susan M | |
| dc.contributor.author | Tsao, Hensin | |
| dc.contributor.author | Aguirre-Ghiso, Julio A | |
| dc.contributor.author | Soengas, Maria S | |
| dc.contributor.author | Weeraratna, Ashani T | |
| dc.contributor.author | Flaherty, Keith T | |
| dc.contributor.author | Herlyn, Meenhard | |
| dc.contributor.author | Sosman, Jeffrey A | |
| dc.contributor.author | Tawbi, Hussein A | |
| dc.contributor.author | Pavlick, Anna C | |
| dc.contributor.author | Cassidy, Pamela B | |
| dc.contributor.author | Chandra, Sunandana | |
| dc.contributor.author | Chapman, Paul B | |
| dc.contributor.author | Daud, Adil | |
| dc.contributor.author | Eroglu, Zeynep | |
| dc.contributor.author | Ferris, Laura K | |
| dc.contributor.author | Fox, Bernard A | |
| dc.contributor.author | Gershenwald, Jeffrey E | |
| dc.contributor.author | Gibney, Geoffrey T | |
| dc.contributor.author | Grossman, Douglas | |
| dc.contributor.author | Hanks, Brent A | |
| dc.contributor.author | Hanniford, Douglas | |
| dc.contributor.author | Hernando, Eva | |
| dc.contributor.author | Jeter, Joanne M | |
| dc.contributor.author | Johnson, Douglas B | |
| dc.contributor.author | Khleif, Samir N | |
| dc.contributor.author | Kirkwood, John M | |
| dc.contributor.author | Leachman, Sancy A | |
| dc.contributor.author | Mays, Darren | |
| dc.contributor.author | Nelson, Kelly C | |
| dc.contributor.author | Sondak, Vernon K | |
| dc.contributor.author | Sullivan, Ryan J | |
| dc.contributor.author | Merlino, Glenn | |
| dc.contributor.author | Soengas, MS | |
| dc.contributor.funder | National Institutes of Health (Estados Unidos) | |
| dc.contributor.funder | Melanoma Research Foundation | |
| dc.contributor.funder | InterMEL | |
| dc.contributor.funder | Michael and Patricia Booker Melanoma Research Endowment | |
| dc.contributor.funder | Robert and Lynne Grossman Family Foundation | |
| dc.date.accessioned | 2024-10-29T09:54:53Z | |
| dc.date.available | 2024-10-29T09:54:53Z | |
| dc.date.issued | 2021-05-15 | |
| dc.description | The authors are indebted to Dr. Robyn Burns, Science Officer for the Melanoma Research Foundation, for her expert assistance with the preparation of this article. Research reported in this publication was supported, in part, by the NIH SPORE grants (1P50CA221703 to J.E. Gershenwald and P50CA225450 to E. Hernando), DoD/CDMRP Team Science Award (CA170374 to J.E. Gershenwald), the Robert and Lynne Grossman Family Foundation (to J.E. Gershenwald), the Michael and Patricia Booker Melanoma Research Endowment (to J.E. Gershenwald), philanthropic contributions to the Melanoma Moon Shots Program ofMDAnderson (to J.E. Gershenwald), NIH intramural research program (ZIABC008756 to G. Merlino), the InterMEL P01 (P01CA206980 to E. Hernando), and the Melanoma Research Foundation. | |
| dc.description.abstract | Five years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma. Since then, remarkable progress has been made on both the basic and clinical research fronts. However, the incidence, recurrence, and death rates for melanoma remain unacceptably high and significant challenges remain. Hence, the MRF Scientific Advisory Council and Breakthrough Consortium, a group that includes clinicians and scientists, reconvened to facilitate intensive discussions on thematic areas essential to melanoma researchers and patients alike, prevention, detection, diagnosis, metastatic dormancy and progression, response and resistance to targeted and immune-based therapy, and the clinical consequences of COVID-19 for patients with melanoma and providers. These extensive discussions helped to crystalize our understanding of the challenges and opportunities facing the broader melanoma community today. In this report, we discuss the progress made since the last MRF assessment, comment on what remains to be overcome, and offer recommendations for the best path forward. | |
| dc.description.peerreviewed | Sí | |
| dc.format.number | 10 | |
| dc.format.page | 2678-2697 | |
| dc.format.volume | 27 | |
| dc.identifier.citation | Clin Cancer Res . 2021 May 15;27(10):2678-2697 | |
| dc.identifier.pmc | https://pmc.ncbi.nlm.nih.gov/articles/PMC8127340/pdf/nihms-1659932.pdf | |
| dc.identifier.pubmedID | 33414132 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12105/25363 | |
| dc.language.iso | eng | |
| dc.publisher | American Association for Cancer Research (AACR) | |
| dc.relation.publisherversion | http://www. 10.1158/1078-0432.CCR-20-4092 | |
| dc.repisalud.institucion | CNIO | |
| dc.repisalud.orgCNIO | CNIO::Grupos de investigación::Grupo de Melanoma | |
| dc.rights.accessRights | open access | |
| dc.rights.license | Attribution 4.0 International | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | TARGETED THERAPY | |
| dc.subject | SYSTEMIC THERAPY | |
| dc.subject | IMMUNOTHERAPY | |
| dc.subject | RECOMMENDATIONS | |
| dc.subject | ASSOCIATION | |
| dc.subject | MORTALITY | |
| dc.subject | SUNBURN | |
| dc.subject | TUMOR | |
| dc.title | The State of Melanoma: Emergent Challenges and Opportunities. | |
| dc.type | research article | |
| dc.type.hasVersion | VoR | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 1e509973-403a-4c27-84e4-e6e660f67f68 | |
| relation.isAuthorOfPublication.latestForDiscovery | 1e509973-403a-4c27-84e4-e6e660f67f68 | |
| relation.isFunderOfPublication | d863b318-3e6b-4cfc-81bb-a6d112b1f86e | |
| relation.isFunderOfPublication.latestForDiscovery | d863b318-3e6b-4cfc-81bb-a6d112b1f86e | |
| relation.isPublisherOfPublication | feeb2648-1129-4dba-838d-68d8d9be6f57 | |
| relation.isPublisherOfPublication.latestForDiscovery | feeb2648-1129-4dba-838d-68d8d9be6f57 |


